The company said, “The Company is reaffirming its full-year 2025 revenue outlook, reflecting confidence in its continued commercial execution and portfolio performance.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals reports Q1 EPS 68c, consensus 53c
- Catalyst Pharma Reports Record Q1 2025 Financial Results
- CPRX Earnings this Week: How Will it Perform?
- Catalyst Pharmaceuticals price target raised to $34 from $33 at BofA
- Catalyst Pharmaceuticals announces Health Canada’s acceptance of AGAMREE NDS